Astellas to Acquire AMEVIVE(R) (alefacept); Acquisition of Psoriasis Product Deepens Astellas' Commitment to Dermatology Franchise.DEERFIELD, Ill. and CAMBRIDGE, Mass. -- Astellas Pharma US, Inc. and Biogen Idec Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BIIB BIIB Basic Imagery Interpretation Brief ) today announced that an agreement for Astellas to purchase the worldwide rights to AMEVIVE(R) (alefacept) was executed as of March 31, 2006. AMEVIVE is a biologic anti-inflammatory compound used in the treatment of moderate-to-severe plaque psoriasis. Under the terms of the agreement, Astellas would acquire the worldwide rights to AMEVIVE in all indications from Biogen Idec. Biogen Idec would continue to manufacture AMEVIVE and supply product to Astellas. The parties anticipate closing the transaction as early as mid-April. "The acquisition of a well-established product such as AMEVIVE strengthens our North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. Dermatology franchise and provides Astellas an opportunity to continue offering physicians this effective option for the treatment of moderate-to-severe plaque psoriasis," stated William Fitzsimmons, Pharm.D., Senior Vice President, Business Development at Astellas Pharma US, Inc. About AMEVIVE AMEVIVE is the first biologic approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. for the treatment of moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy systemic therapy Therapeutics Any therapy that reaches target tissues via the systemic circulation or phototherapy Phototherapy Definition Phototherapy, or light therapy, is the administration of doses of bright light in order to normalize the body's internal clock and/or relieve depression. . AMEVIVE is a prescription medication that is injected by your doctor (15 mg IM, into the muscle) once a week, for a total of 12 doses. AMEVIVE was approved by the US FDA in January 2003. The most serious adverse reactions found in clinical trials were: lymphopenia, malignancies, serious infections requiring hospitalization and hypersensitivity hypersensitivity, heightened response in a body tissue to an antigen or foreign substance. The body normally responds to an antigen by producing specific antibodies against it. The antibodies impart immunity for any later exposure to that antigen. . Amevive is contraindicated in patients infected with HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and in patients who are allergic to any of the components of Amevive For more information about AMEVIVE, including prescribing information call 1-866-AMEVIVE or visit www.amevive.com. About Chronic Plaque Psoriasis Psoriasis is a chronic but treatable autoimmune skin disease. Roughly two percent of the world's population has psoriasis. In the US, psoriasis affects 4.5-6 million people, and about 1.2 million people have a moderate to severe form of chronic plaque psoriasis. While psoriasis is not typically life threatening, it can greatly affect appearance, self-esteem, and quality of life. Chronic plaque psoriasis can develop anywhere on the skin, though it usually appears on the scalp, knees, elbows, and trunk. About Astellas Pharma US, Inc. Astellas Pharma US, Inc. is a subsidiary of Astellas Pharma Inc., located in Tokyo, a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. In April 2005, the company was formed through the merger of Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. The organization is committed to becoming a global mega pharmaceutical company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. For more information about Astellas, please visit www.astellas.com/us. About Biogen Idec Inc. Biogen Idec creates new standards of care Standards of care are medical or psychological treatment guidelines, and can be general or specific. They specify appropriate treatment protocols based on scientific evidence, and collaboration between medical and/or psychological professionals involved in the treatment of a given in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For press releases and additional information about the company, please visit www.biogenidec.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion